Inotec AMD, manufacturer of NATROX® Oxygen Wound Therapy, is delighted to share newly published randomised controlled trial (RCT) results[1]. The trial involved 145 patients with previously non-healing diabetic foot ulcers (DFUs) and compared the effects of standard care against a combination of standard care plus NATROX® Oxygen Wound Therapy. Patients completing the therapy experienced 71% greater healing rates and 73% greater reduction in wound size using NATROX®. These results offer hope to patients suffering from chronic wounds.

What is NATROX®

NATROX® Oxygen Wound Therapy is a class II medical device that uses the natural healing properties of oxygen. The product was designed specifically to heal chronic wounds. Originally invented by the company’s founder to aid a family member enduring severe pain from a non-healing ulcer, Inotec was established to transform the quality of life for patients with chronic wounds through its innovative topical oxygen therapy. Due to its small size, the device is easily portable and means patients receive treatment 24/7, leading to better healing outcomes.